256 related articles for article (PubMed ID: 24333131)
1. A myostatin and activin decoy receptor enhances bone formation in mice.
Bialek P; Parkington J; Li X; Gavin D; Wallace C; Zhang J; Root A; Yan G; Warner L; Seeherman HJ; Yaworsky PJ
Bone; 2014 Mar; 60():162-71. PubMed ID: 24333131
[TBL] [Abstract][Full Text] [Related]
2. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
4. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
5. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
[TBL] [Abstract][Full Text] [Related]
6. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
8. Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss.
Guo W; Pencina KM; O'Connell K; Montano M; Peng L; Westmoreland S; Glowacki J; Bhasin S
Bone; 2017 Apr; 97():209-215. PubMed ID: 28132908
[TBL] [Abstract][Full Text] [Related]
9. A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength.
Arounleut P; Bialek P; Liang LF; Upadhyay S; Fulzele S; Johnson M; Elsalanty M; Isales CM; Hamrick MW
Exp Gerontol; 2013 Sep; 48(9):898-904. PubMed ID: 23832079
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Jeong Y; Rafique A; Krueger P; Kleiner S; Phillips CL
J Bone Miner Res; 2022 May; 37(5):938-953. PubMed ID: 35195284
[TBL] [Abstract][Full Text] [Related]
11. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
[TBL] [Abstract][Full Text] [Related]
12. Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model.
Puolakkainen T; Rummukainen P; Lehto J; Ritvos O; Hiltunen A; Säämänen AM; Kiviranta R
PLoS One; 2017; 12(7):e0180593. PubMed ID: 28704409
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
14. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Soluble Activin Type IIB Receptor Ameliorates Ovariectomy-Induced Bone Loss and Fat Gain in Mice.
Puolakkainen T; Rummukainen P; Pihala-Nieminen V; Ritvos O; Savontaus E; Kiviranta R
Calcif Tissue Int; 2022 Apr; 110(4):504-517. PubMed ID: 35024891
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.
Béchir N; Pecchi É; Relizani K; Vilmen C; Le Fur Y; Bernard M; Amthor H; Bendahan D; Giannesini B
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E539-49. PubMed ID: 26837807
[TBL] [Abstract][Full Text] [Related]
17. Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta.
Tauer JT; Rauch F
Bone; 2019 Nov; 128():115036. PubMed ID: 31419601
[TBL] [Abstract][Full Text] [Related]
18. A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.
Wang Q; Guo T; Portas J; McPherron AC
Int J Biol Sci; 2015; 11(2):199-208. PubMed ID: 25561902
[TBL] [Abstract][Full Text] [Related]
19. Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.
Omosule CL; Gremminger VL; Aguillard AM; Jeong Y; Harrelson EN; Miloscio L; Mastaitis J; Rafique A; Kleiner S; Pfeiffer FM; Zhang A; Schulz LC; Phillips CL
J Bone Miner Res; 2021 Apr; 36(4):739-756. PubMed ID: 33249643
[TBL] [Abstract][Full Text] [Related]
20. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
